Novartis takes rights to Abogen's mRNA T cell engager for $575M upfront
Novartis will pay Abogen Biosciences $575 million upfront for exclusive worldwide rights to an early-stage CD19xCD3 T cell engager, which is the Chinese biotech's lead asset. Abogen could get up to about $7.2 billion further ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.